Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study.

[1]  P. Lambin,et al.  Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Lambin,et al.  Individualized radical radiotherapy of non-small-cell lung cancer based on normal tissue dose constraints: a feasibility study. , 2008, International journal of radiation oncology, biology, physics.

[3]  V. Johnson,et al.  Radiation pneumonitis: correlation of toxicity with pulmonary metabolic radiation response. , 2008, International journal of radiation oncology, biology, physics.

[4]  P. Lambin,et al.  Radiation dose prescription for non-small-cell lung cancer according to normal tissue dose constraints: an in silico clinical trial. , 2008, International journal of radiation oncology, biology, physics.

[5]  P. Lambin,et al.  HI-CHART: a phase I/II study on the feasibility of high-dose continuous hyperfractionated accelerated radiotherapy in patients with inoperable non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[6]  T. Lawrence,et al.  The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[7]  Lujun Zhao,et al.  Inhibition of the Tumor Necrosis Factor-α Pathway Is Radioprotective for the Lung , 2008, Clinical Cancer Research.

[8]  J. Curtis,et al.  The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. , 2008, Lung cancer.

[9]  J. Hasday,et al.  Tobacco Smoking Inhibits Expression of Proinflammatory Cytokines and Activation of IL-1R-Associated Kinase, p38, and NF-κB in Alveolar Macrophages Stimulated with TLR2 and TLR4 Agonists1 , 2007, The Journal of Immunology.

[10]  P. Rubin,et al.  Can Serum Markers Be Used to Predict Acute and Late Toxicity in Patients With Lung Cancer?: Analysis of RTOG 91-03 , 2007, American journal of clinical oncology.

[11]  Indrin J Chetty,et al.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Randall K Ten Haken,et al.  Physical models and simpler dosimetric descriptors of radiation late toxicity. , 2007, Seminars in radiation oncology.

[13]  Philippe Lambin,et al.  Routine individualised patient dosimetry using electronic portal imaging devices. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  A. Rojas,et al.  Toxicity and outcome of a phase II trial of taxane‐based neoadjuvant chemotherapy and 3‐dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer , 2006, Cancer.

[15]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[16]  J. Blay,et al.  Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. T. Ten Haken,et al.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.

[18]  M. Benderitter,et al.  Pravastatin Limits Endothelial Activation after Irradiation and Decreases the Resulting Inflammatory and Thrombotic Responses , 2005, Radiation research.

[19]  Tae Hyun Kim,et al.  Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. , 2005, Radiology.

[20]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[21]  G. Rodrigues.  A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  O. Holmberg,et al.  Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  M. Socinski,et al.  Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  David Binns,et al.  Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. , 2004, International journal of radiation oncology, biology, physics.

[25]  Suresh Senan,et al.  Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  B. Fenton,et al.  Effect of Administration of Lovastatin on the Development of Late Pulmonary Effects after Whole-Lung Irradiation in a Murine Model , 2004, Radiation research.

[27]  H. Kampinga,et al.  Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[28]  M. Martel,et al.  Results following treatment to doses of 92.4 or 102.9 Gy on a phase I dose escalation study for non-small cell lung cancer. , 2004, Lung cancer.

[29]  André Wambersie,et al.  The International Commission on Radiation Units and Measurements , 2001, Journal of the ICRU.

[30]  G. Ceresoli,et al.  Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[31]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[32]  A. Rojas,et al.  Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer. , 2002, Clinical oncology (Royal College of Radiologists (Great Britain)).

[33]  Andrew Jackson,et al.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[34]  M T Munley,et al.  Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[35]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Ling,et al.  Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer. , 2000, Cancer journal.

[37]  T. J. Robnett,et al.  Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. , 2000, International journal of radiation oncology, biology, physics.

[38]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[39]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[40]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Melvin L. Griem,et al.  Prescribing, Recording, and Reporting Photon Beam Therapy , 1994 .

[42]  R K Ten Haken,et al.  Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. , 1994, International journal of radiation oncology, biology, physics.

[43]  Icru.  Prescribing, recording, and reporting photon beam therapy , 1993 .